Leukemic cell products down-regulate human dendritic cell differentiation

Cancer Immunology, Immunotherapy

Volumn 59, Issue 11, 2010, Pages 1645-1653

  Motta, Juliana Maria ^a   Nascimento, Clarissa Rodrigues ^a   Rumjanek, Vivian Mary ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Dendritic cell differentiation; IL 1 ; Leukemic cell products; TNF

Indexed keywords

CD14 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 4; T6 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL STRAIN HL 60; CELL STRAIN K 562; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DAUDI CELL; DENDRITIC CELL; DOWN REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUPERNATANT; TUMOR MICROENVIRONMENT;

ANTIGENS, CD14; BLOTTING, WESTERN; BURKITT LYMPHOMA; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; LEUKEMIA; MONOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77958036074     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0890-5     Document Type: Article

References (34)

1. Biemer JJ (1990) Malignant lymphomas associated with immunodeficiency states. Ann Clin Lab Sci 20:175-191
2. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4:11-22 (Pubitemid 38111131)
3. Shunyakov L, Ryan CK, Sahasrabudhe DM, Khorana AA (2004) The influence of host response on colorectal cancer prognosis. Clin Colorectal Cancer 4:38-45
4. Costello RT, Gastaut JA, Olive D (1999) Mechanisms of tumor escape from immunologic response. Rev Med Interne 20:579-588
5. Algarra I, García-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53:904-910
6. Shurin M, Gabrilovich D (2001) Regulation of the dendritic cell system by tumor. Cancer Res Ther Control 11:65-78
7. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274
8. Elgert KD, Alleva DG, Mullins DW (1998) Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64:275-290
9. Chomarat P, Banchereau J, Davoust J, Palucka AK (2000) IL-6 switches the diferentiation of monocytes from dendritic cells to macrophages. Nat Immunol 1:510-514
10. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L, Mantovani A (1998) IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 28:359-369
11. Kalinski P, Schuitemaker JH, Hilkens CM, Kapsenberg ML (1998) Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the inal dendritic cell maturation and are resistant to further modulation. J Immunol 161:2804-2809
12. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252
13. Romani N, Gruner S, Brang D, Kämpgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83-93
14. Peters JH, Gieseler R, Thiele B, Steinbach F (1996) Dendritic cells: from ontogenetic orphans to myelomonocytic descendants. Immunol Today 17:273-278
15. Romani N, Reider D, Heuer M, Ebner S, Kämpgen E, Eibl B, Niederwieser D, Schuler G (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196:137-151
16. Aalamian M, Tourkova IL, Chatta GS, Lilja H, Huland E, Huland H, Shurin GV, Shurin MR (2003) Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J Urol 170:2026-2030
17. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM Jr (2001) Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 61:363-369
18. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, Blay JY (1998) Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92:4778-4791
19. Bharadwaj U, Li M, Zhang R, Chen C, Yao Q (2007) Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell diferentiation and activation. Cancer Res 67:5479-5488
20. Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inlammation, and cancer. J Clin Invest 117:1175-1183
21. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25:387-408
22. Zhou LJ, Tedder TF (1996) CD14+ blood monocytes can diferentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 93:2588-2592
23. Blanco P, Palucka AK, Pascual V, Banchereau J (2008) Dendritic cells and cytokines in human inlammatory and autoimmune diseases. Cytokine Growth Factor Rev 19:41-52
24. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109-1118
25. Sombroek CC, Stam AG, Masterson AJ, Lougheed SM, Schakel MJ, Meijer CJ, Pinedo HM, van den Eertwegh AJ, Scheper RJ, de Gruijl TD (2002) Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell diferentiation. J Immunol 168:4333-4343
26. Kiertscher SM, Luo J, Dubinett SM, Roth MD (2000) Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 164:1269-1276
27. Shurin MR, Yurkovetsky ZR, Tourkova IL, Balkir L, Shurin GV (2002) Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int J Cancer 101:61-68
28. Lozzio CB, Lozzio BB (1975) Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45:321-334
29. Gallagher R, Collins S, Trujillo J, Mccredie K, Ahearn M, Tsai S, Metzgar R, Aulakh G, Ting R, Ruscetti F, Gallo R (1979) Characterization of the continuous, diferentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54:713-733
30. Adams A, Strander H, Cantell K (1975) Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to interferon. J Gen Virol 28:207-217
31. Ogden CA, Pound JD, Batth BK, Owens S, Johannessen I, Wood K, Gregory CD (2005) Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J Immunol 174:3015-3023
32. Hillenbrand EE, Neville AM, Coventry BJ (1999) Immunohisto-chemical localization of CD1a-positive putative dendritic cells in human breast tumours. Br J Cancer 79:940-944
33. Joo HG, Fleming TP, Tanaka Y, Dunn TJ, Linehan DC, Goedegebuure PS, Eberlein TJ (2002) Human dendritic cells induce tumor-speciic apoptosis by soluble factors. Int J Cancer 102:20-28
34. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096-1103